---
title: "Gentian Q2 EBITDA swings to NOK 8.1 million; revenue rises 14% to NOK 49.8 million vs Q2 FY25"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292151593.md"
description: "Gentian Diagnostics reported a Q2 2026 net profit of NOK 4.42 million, reversing a prior-year loss, with revenue rising 14% to NOK 49.8 million. EBITDA swung to NOK 8.12 million, and gross margin widened by 11 percentage points to 55%. US sales surged 45%, while Asia sales fell 25%. fCAL turbo sales grew 35%, and cystatin C sales rose 5%. Management maintained R&D spending and introduced new pipeline governance targeting over 20% return on capital employed."
datetime: "2026-07-09T05:35:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292151593.md)
  - [en](https://longbridge.com/en/news/292151593.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292151593.md)
generator: "portal-rs"
---

# Gentian Q2 EBITDA swings to NOK 8.1 million; revenue rises 14% to NOK 49.8 million vs Q2 FY25

-   Gentian Diagnostics posted Q2 2026 net profit of NOK 4.42 million, swinging from a net loss a year earlier as sales rose 14% to NOK 49.8 million. \* EBITDA climbed to NOK 8.12 million, while gross margin widened 11 percentage points to 55%. \* US sales jumped 45% to NOK 10.4 million, while Asia sales fell 25% to NOK 7.4 million. \* fCAL turbo sales increased 35% to NOK 17.3 million, while cystatin C sales rose 5% to NOK 18.3 million. \* Management kept R&D spending levels, introduced new pipeline governance targeting more than 20% return on capital employed on new projects. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gentian Diagnostics ASA published the original content used to generate this news brief on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

## Related News & Research

- [Orkla Non-GAAP EPS of NOK 1.60, revenue of NOK 16.7B](https://longbridge.com/en/news/296456178.md)
- [Vow ASA GAAP EPS of NOK 0.02, revenue of NOK 252.9M](https://longbridge.com/en/news/296331370.md)
- [Akastor GAAP EPS of NOK 0.28, revenue of NOK 338M](https://longbridge.com/en/news/296592801.md)
- [Zaptec Q2 FY26 EBITDA rises to NOK 69 million; revenue climbs to NOK 506 million](https://longbridge.com/en/news/296304044.md)
- [Zaptec (OB:ZAP) Stock Price Reflects A Sharper Profit Engine](https://longbridge.com/en/news/296529847.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**